Bone Health

Immunology

Hematology

Respiratory

Dermatology

Diabetes

Gastroenterology

Neurology

Oncology

Ophthalmology

Rare Disease

Rheumatology

News

All News

Product Approvals and Launches

Media

All Videos

Insights

Interviews

Peer Exchange

Podcasts

Stakeholder Summit

Compendia

Conferences

Conference Coverage

Conference Listing

CME/CE

Resources

Authors

Biosimilar Resources

Interactive Tools

Partners

Polls and Quizzes

WHEN CHOICE ARRIVES: Competition & Consequences

Subscribe

BIOSIMILAR APPROVALS

Cameron Santoro is an associate editor for The Center for Biosimilars

Articles

Sophia Humphreys, PharmD, MHA, BCBBS, emphasized that legislative support and formulary changes are crucial for overcoming unique challenges in specialty pharmacies and driving the growth of biosimilar adoption, which has significant cost saving potential in the next decade.

Unlocking Biosimilar Potential in Specialty Pharmacies With Legislative Support, Formulary Changes

Dracey Poore, MS, director of biosimilars and emerging therapies at Cardinal Health, highlighted that biosimilars saved $36 billion over the last decade by improving patient access and the supply chain, but continued education and a robust pipeline are crucial for future growth. 

Decade of Biosimilars Yields $36 Billion in Savings and Strengthens Supply Chain

Biosimilars are proving to be a game-changing solution in the fight against inflammatory bowel disease (IBD), offering a cost-effective alternative to biologics with similar efficacy and safety, while innovative drug delivery systems promise to further enhance treatment outcomes and accessibility for millions worldwide.

The Growing Impact of Biosimilars in IBD Care

Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.

Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick

About

Editorial

Contact

Advisory Board

Do Not Sell My Information

Terms & Conditions

Privacy Policy

Center for Biosimilars®

Facebook

Twitter

LinkedIn

Business Practice

Business

Development

Legal

Policy

Practice

Regulatory

1rem

This new eBook from The Center for Biosimilars

® tells the compelling story of how biosimilar development and uptake have been affected by COVID-19. Read it and find out how biosimilars may emerge from the pandemic as a more powerful, more valuable force in lower-cost medicine.

The Disruptor: How Coronavirus Disease 2019 (COVID-19) Has Affected the Development and Uptake of Biosimilars

Are you ready for the upcoming 2020 transition of insulins and other therapeutic proteins to US regulation as biologics and biosimilars? Find out what you need to know about the regulatory change with a new ebook from The Center for Biosimilars®.

Preparing for the 2020 Regulatory Transition of Insulin and Other Therapeutic Proteins

Strategies for Successful Adoption of Biosimilars in Practice: Takeaways From the West Cancer Center Experience

Biosimilars 101:  Practice Concerns, Market Acceptance, and the Biosimilars Pipeline

Pfizer Global Biosimilars Commercial Lead, Roman Irsiegler, gives his thoughts on why a sustainable biosimilars market is critical for the healthcare industry, and what stakeholders can do to achieve it.

How can we achieve a long-term sustainable biosimilars market?

What is key to achieving a long-term sustainable biosimilars market?

Resources

Strategies for Successful Adoption of Biosimilars in Practice: Takeaways From the West Cancer Center Experience

Date:

Biosimilars 101: Practice Concerns, Market Acceptance, and the Biosimilars Pipeline

Date:

How can we achieve a long-term sustainable biosimilars market?

Date:

What is key to achieving a long-term sustainable biosimilars market?

Date: